Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280


New windows open for immunotherapy in lung cancer.

Hendriks L, Besse B.

Nature. 2018 Jun;558(7710):376-377. doi: 10.1038/d41586-018-05312-9. No abstract available.


Long leptomeningeal responses with brigatinib in two heavily pre-treated ALK-rearranged non-small cell lung cancer patients.

Geraud A, Mezquita L, Bigot F, Caramella C, Planchard D, Le Pechoux C, Besse B.

J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30683-X. doi: 10.1016/j.jtho.2018.05.033. [Epub ahead of print] No abstract available.


Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment.

El Rassy E, Botticella A, Kattan J, Le Péchoux C, Besse B, Hendriks L.

Cancer Treat Rev. 2018 May 31;68:69-79. doi: 10.1016/j.ctrv.2018.05.015. [Epub ahead of print] Review.


Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.

Slimano F, Netzer F, Borget I, Lemare F, Besse B.

Int J Clin Pharm. 2018 May 9. doi: 10.1007/s11096-018-0649-1. [Epub ahead of print]


Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.

Remon J, Besse B.

Front Oncol. 2018 Apr 11;8:88. doi: 10.3389/fonc.2018.00088. eCollection 2018. Review.


Should surgery be part of the multimodality treatment for stage IIIB non-small cell lung cancer?

Collaud S, Provost B, Besse B, Fabre D, Le Chevalier T, Mercier O, Mussot S, Fadel E.

J Surg Oncol. 2018 Mar 24. doi: 10.1002/jso.25042. [Epub ahead of print]


Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.

Levy A, Faivre-Finn C, Hasan B, De Maio E, Berghoff AS, Girard N, Greillier L, Lantuéjoul S, O'Brien M, Reck M, Dingemans AC, Novello S, Berghmans T, Besse B, Hendriks L; Young Investigators EORTC Lung Cancer Group (YI EORTC LCG).

Eur J Cancer. 2018 Apr;93:37-46. doi: 10.1016/j.ejca.2018.01.067. Epub 2018 Feb 21.


Are liquid biopsies a surrogate for tissue EGFR testing?

Goldman JW, Noor ZS, Remon J, Besse B, Rosenfeld N.

Ann Oncol. 2018 Jan 1;29(suppl_1):i38-i46. doi: 10.1093/annonc/mdx706.


Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazieres J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenegre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B.

ERJ Open Res. 2018 Feb 13;4(1). pii: 00058-2017. doi: 10.1183/23120541.00058-2017. eCollection 2018 Jan.


Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.

Eur J Cancer. 2018 Mar;91:21-29. doi: 10.1016/j.ejca.2017.12.008. Epub 2018 Jan 10.


Progress in the Management of Advanced Thoracic Malignancies in 2017.

Ferrara R, Mezquita L, Besse B.

J Thorac Oncol. 2018 Mar;13(3):301-322. doi: 10.1016/j.jtho.2018.01.002. Epub 2018 Jan 11. Review.


Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B.

JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.


Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment.

Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, Champiat S, Voisin AL, Lambotte O.

Clin Microbiol Infect. 2018 Mar;24(3):216-218. doi: 10.1016/j.cmi.2017.12.003. Epub 2017 Dec 18. No abstract available.


Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB.

J Thorac Oncol. 2018 Apr;13(4):576-584. doi: 10.1016/j.jtho.2017.11.131. Epub 2017 Dec 13.


LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.

Facchinetti F, Bluthgen MV, Tergemina-Clain G, Faivre L, Pignon JP, Planchard D, Remon J, Soria JC, Lacroix L, Besse B.

Lung Cancer. 2017 Oct;112:62-68. doi: 10.1016/j.lungcan.2017.08.002. Epub 2017 Aug 7.


Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.

Mezquita L, Charrier M, Faivre L, Dupraz L, Lueza B, Remon J, Planchard D, Bluthgen MV, Facchinetti F, Rahal A, Polo V, Gazzah A, Caramella C, Adam J, Pignon JP, Soria JC, Chaput N, Besse B.

Lung Cancer. 2017 Oct;112:10-15. doi: 10.1016/j.lungcan.2017.07.004. Epub 2017 Jul 29.


Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.

Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, Balleyguier C, Planchard D, Gazzah A, Soria JC, Marabelle A, Besse B, Caramella C.

Eur J Cancer. 2018 Jan;88:38-47. doi: 10.1016/j.ejca.2017.10.017. Epub 2017 Nov 26.


Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.

Ferrara R, Auger N, Auclin E, Besse B.

J Thorac Oncol. 2018 Jan;13(1):27-45. doi: 10.1016/j.jtho.2017.10.021. Epub 2017 Nov 8. Review.


Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.

Sakr R, Renneville A, Saada V, Cotteret S, Martin JE, Droin N, Selimoglu-Buet D, Besse B, Hollebecque A, Marzac C, Pasquier F, Micol JB, De Botton S, Mir O, Solary E, Willekens C.

Leuk Lymphoma. 2017 Nov 8:1-4. doi: 10.1080/10428194.2017.1397669. [Epub ahead of print] No abstract available.


Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ.

Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23.


A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

Soria JC, Adjei AA, Bahleda R, Besse B, Ferte C, Planchard D, Zhou J, Ware J, Morrissey K, Shankar G, Lin W, Schutzman JL, Dy GK, Groen HJM.

Eur J Cancer. 2017 Nov;86:186-196. doi: 10.1016/j.ejca.2017.08.027. Epub 2017 Oct 6.


Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.

Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M; French Cooperative Thoracic Intergroup (IFCT).

Ann Oncol. 2017 Nov 1;28(11):2715-2724. doi: 10.1093/annonc/mdx404.


Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE.

Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.


Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.

Mahjoubi L, Gazzah A, Marabelle A, Le Roy Ladurie F, Lambotte O, Caramella C, Adam J, Besse B, Soria JC.

Eur J Cancer. 2017 Nov;85:155-157. doi: 10.1016/j.ejca.2017.07.049. Epub 2017 Sep 13. No abstract available.


Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?

Ferrara R, Mezquita L, Auclin E, Chaput N, Besse B.

Cancer Treat Rev. 2017 Nov;60:60-68. doi: 10.1016/j.ctrv.2017.08.003. Epub 2017 Aug 24. Review.


Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapy.

Mazza C, Remon J, Honoré C, Besse B.

Lung Cancer. 2017 Sep;111:59-60. doi: 10.1016/j.lungcan.2017.06.011. Epub 2017 Jul 8.


Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer.

Jovelet C, Madic J, Remon J, Honoré A, Girard R, Rouleau E, André B, Besse B, Droniou M, Lacroix L.

PLoS One. 2017 Aug 22;12(8):e0183319. doi: 10.1371/journal.pone.0183319. eCollection 2017.


EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

Tomasini P, Brosseau S, Mazières J, Merlio JP, Beau-Faller M, Mosser J, Wislez M, Ouafik L, Besse B, Rouquette I, Debieuvre D, Escande F, Westeel V, Audigier-Valette C, Missy P, Langlais A, Morin F, Moro-Sibilot D, Zalcman G, Barlesi F.

Eur Respir J. 2017 Aug 10;50(2). pii: 1700514. doi: 10.1183/13993003.00514-2017. Print 2017 Aug.


Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort.

Basse C, Thureau S, Bota S, Dansin E, Thomas PA, Pichon E, Lena H, Massabeau C, Clément-Duchene C, Massard G, Westeel V, Quantin X, Oulkhouir Y, Danhier S, Lerouge D, Tanguy R, Thillays F, Le Pechoux C, Dubray B, Thiberville L, Besse B, Girard N.

J Thorac Oncol. 2017 Nov;12(11):1715-1722. doi: 10.1016/j.jtho.2017.07.023. Epub 2017 Jul 31.


An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains.

Andre-Garnier E, Besse B, Rodallec A, Ribeyrol O, Ferre V, Luco C, Le Guen L, Bourgeois N, Gournay J, Billaud E, Raffi F, Coste-Burel M, Imbert-Marcille BM.

PLoS One. 2017 Jul 20;12(7):e0179562. doi: 10.1371/journal.pone.0179562. eCollection 2017.


A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.

Lindsay CR, Faugeroux V, Michiels S, Pailler E, Facchinetti F, Ou D, Bluthgen MV, Pannet C, Ngo-Camus M, Bescher G, Caramella C, Billiot F, Remon J, Planchard D, Soria JC, Besse B, Farace F.

Ann Oncol. 2017 Jul 1;28(7):1523-1531. doi: 10.1093/annonc/mdx156.


Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.

Gion M, Remon J, Caramella C, Soria JC, Besse B.

Lung Cancer. 2017 Jun;108:72-74. doi: 10.1016/j.lungcan.2017.02.022. Epub 2017 Feb 27.


CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies.

Remon J, Abedallaa N, Taranchon-Clermont E, Bluthgen V, Lindsay CR, Besse B, Thomas de Montpréville V.

Lung Cancer. 2017 Jun;108:168-172. doi: 10.1016/j.lungcan.2017.03.019. Epub 2017 Mar 31.


A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.

Glisson B, Besse B, Dols MC, Dubey S, Schupp M, Jain R, Jiang Y, Menon H, Nackaerts K, Orlov S, Paz-Ares L, Ramlau R, Tang R, Zhang Y, Zhu M.

Clin Lung Cancer. 2017 Nov;18(6):615-625.e8. doi: 10.1016/j.cllc.2017.05.007. Epub 2017 May 10.


Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.

Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin AL, Pontoizeau C, Coutte L, Pertuiset E, Mouterde G, Fain O, Lambotte O, Mariette X.

Ann Rheum Dis. 2017 Oct;76(10):1747-1750. doi: 10.1136/annrheumdis-2017-211216. Epub 2017 Jun 9.


Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.

Atlan P, Bayar MA, Lanoy E, Besse B, Planchard D, Ramon J, Raynard B, Antoun S.

Support Care Cancer. 2017 Nov;25(11):3365-3373. doi: 10.1007/s00520-017-3755-z. Epub 2017 Jun 8.


EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.

Thomas De Montpréville V, Ghigna MR, Lacroix L, Lemoine A, Besse B, Mercier O, Fadel É, Dorfmuller P, Le Chevalier T; Institut d’Oncologie Thoracique.

Pathol Res Pract. 2017 Jul;213(7):793-798. doi: 10.1016/j.prp.2017.03.011. Epub 2017 Mar 30.


Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.

Pailler E, Oulhen M, Borget I, Remon J, Ross K, Auger N, Billiot F, Ngo Camus M, Commo F, Lindsay CR, Planchard D, Soria JC, Besse B, Farace F.

Cancer Res. 2017 May 1;77(9):2222-2230. doi: 10.1158/0008-5472.CAN-16-3072.


Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.


Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.

Boros A, Lacroix L, Lacas B, Adam J, Pignon JP, Caramella C, Planchard D, de Montpreville V, Deutsch E, Levy A, Besse B, Le Pechoux C.

Oncotarget. 2017 Apr 11;8(15):25189-25199. doi: 10.18632/oncotarget.15966.


Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

Remon J, Besse B, Soria JC.

BMC Med. 2017 Apr 20;15(1):82. doi: 10.1186/s12916-017-0857-x. No abstract available.


Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.

Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, Descourt R, Dansin E, Audigier-Valette C, Moreau L, Hureaux J, Veillon R, Otto J, Madroszyk-Flandin A, Cortot A, Guichard F, Boudou-Rouquette P, Langlais A, Missy P, Morin F, Moro-Sibilot D.

Oncotarget. 2017 Mar 28;8(13):21903-21917. doi: 10.18632/oncotarget.15746.


Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.

Facchinetti F, Rossi G, Bria E, Soria JC, Besse B, Minari R, Friboulet L, Tiseo M.

Cancer Treat Rev. 2017 Apr;55:83-95. doi: 10.1016/j.ctrv.2017.02.010. Epub 2017 Mar 12. Review.


The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.

Remon J, Menis J, Hasan B, Peric A, De Maio E, Novello S, Reck M, Berghmans T, Wasag B, Besse B, Dziadziuszko R.

Clin Lung Cancer. 2017 Sep;18(5):583-588. doi: 10.1016/j.cllc.2017.02.005. Epub 2017 Mar 1.


Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.

Besse B, Mazières J, Ribassin-Majed L, Barlesi F, Bennouna J, Gervais R, Moreau L, Berard H, Debieuvre D, Molinier O, Moro-Sibilot D, Souquet PJ, Jacquot S, Petit L, Lena H, Pignon JP, Lacas B, Morin F, Milleron B, Zalcman G, Soria JC; Intergroupe Francophone de Cancérologie Thoracique (IFCT).

Ann Oncol. 2017 May 1;28(5):1078-1083. doi: 10.1093/annonc/mdx070.


Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

Remon J, Besse B, Soria JC.

BMC Med. 2017 Mar 13;15(1):55. doi: 10.1186/s12916-017-0819-3. Review. Erratum in: BMC Med. 2017 Apr 20;15(1):82.


Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.

Guibert N, Barlesi F, Descourt R, Léna H, Besse B, Beau-Faller M, Mosser J, Pichon E, Merlio JP, Ouafik L, Guichard F, Mastroianni B, Moreau L, Wdowik A, Sabourin JC, Lemoine A, Missy P, Langlais A, Moro-Sibilot D, Mazières J.

J Thorac Oncol. 2017 Jun;12(6):963-973. doi: 10.1016/j.jtho.2017.02.001. Epub 2017 Feb 9.


Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era.

Remon J, Le Rhun E, Besse B.

Cancer Treat Rev. 2017 Feb;53:128-137. doi: 10.1016/j.ctrv.2016.12.006. Epub 2016 Dec 30. Review.


Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, Howarth K, Gale D, Green E, Plagnol V, Rosenfeld N, Planchard D, Bluthgen MV, Gazzah A, Pannet C, Nicotra C, Auclin E, Soria JC, Besse B.

Ann Oncol. 2017 Apr 1;28(4):784-790. doi: 10.1093/annonc/mdx017.


Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al.

Mezquita L, Besse B.

J Thorac Dis. 2016 Nov;8(11):2997-3002. doi: 10.21037/jtd.2016.11.76. No abstract available.

Supplemental Content

Support Center